Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a retrospective and what the future may hold

다국어 초록 (Multilingual Abstract)

Cardiovascular complications dominate the landscape of chronic kidney diseases (CKD). Endothelial cell dysfunction (ECD) is a well-known culprit of cardiovascular morbidity and it develops in CKD with remarkable frequency. This brief overview of ECD in CKD scans two decades of studies performed in my laboratory, from genetic analyses to proteomic and metabolomics screens. I provide a detailed description of findings related to the premature senescence of endothelial cells, cell transition from the endothelial to mesenchymal phenotype, and stages of development of ECD. Clinical utility of some of these findings is illustrated with data on laser- Doppler flowmetry and imaging in patients with CKD. Some currently available and emerging therapeutic options for the management of ECD are briefly presented.

참고문헌 (Reference)

1 Smirnova IV, "Upregulation of lectinlike oxidized low-density lipoprotein receptor-1(LOX-1)in endothelial cells by nitric oxide deficiency" 287 : F25-F32, 2004

2 Turner J, "Treatment of chronic kidney disease" 81 : 351-362, 2012

3 Addabbo F, "The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction" 174 : 34-43, 2009

4 Schultz E, "Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction" 118 : 1347-1357, 2008

5 Goligorsky MS, "Stress-induced premature senescence of endothelial cells : a perilous state between recovery and point of no return" 16 : 215-219, 2009

6 Goligorsky MS, "Regenerative Nephrology" Elsevier 275-287, 2010

7 Catravas J, "Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits" 128 : 740-746, 1983

8 Himmelfarb J, "Provision of antioxidant therapy in hemodialysis(PATH) : a randomized clinical trial" 25 : 623-633, 2014

9 Pula G, "Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures" 104 : 32-40, 2009

10 Brodsky SV, "Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen" 94 : 377-384, 2004

11 Chen J, "Premature senescence of endothelial cells : Methusaleh's dilemma" 290 : H1729-H1739, 2006

12 Ludmer P, "Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries" 315 : 1046-1051, 1986

13 Li H, "Paradoxical overexpression and translocation of connexin-43 in homocysteine-treated endothelial cells" 282 : H2124-H2133, 2002

14 Stewart J, "Non-invasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure" 287 : H2687-H2696, 2004

15 Mervaala E, "Lipoic acid supplementation prevents angiotensin II-induced renal injury" 64 : 501-508, 2003

16 Kruger A, "Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients : correlation with cardiovascular risk" 70 : 157-164, 2006

17 Stoessel A, "Indolent course of tubulointerstitial disease in a mouse model of subpressor, lowdose nitric oxide synthase inhibition" 295 : F717-F725, 2008

18 Li H, "Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis?" 105 : 1037-1043, 2002

19 Hemmen K, "High-resolution mass spectrometric analysis of the secretome from mouse lung endothelial progenitor cells" 14 : 163-172, 2011

20 Chen J, "Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells" 90 : 1290-1298, 2002

21 Addabbo F, "Glutamine supplementation alleviates vasculopathy and alters plasma metabolome in an in vivo model of endothelial cell dysfunction" 8 : e65458-, 2013

22 Pottier N, "FibromiRs : translating molecular discoveries into new anti-fibrotic drugs" 35 : 119-126, 2014

23 Zeisberg EM, "Fibroblasts in kidney fibrosis emerge via endothelial-tomesenchymal transition" 19 : 2282-2287, 2008

24 Gaengel K, "Endothelial–mural cell signaling in vascular development and angiogenesis" 29 : 630-638, 2009

25 Li J, "Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice" 175 : 1380-1388, 2009

26 Li H, "Endothelial gene responses to homocysteine : relation to atherosclerosis" 10 : 164-169, 2002

27 Goligorsky MS, "Endothelial cell dysfunction : can’t live with it, how to live without it" 288 : F871-F880, 2005

28 Miyata T, "Diabetic nephropathy:are there new and potentially promising therapies targeting oxygen biology?" 84 : 693-702, 2013

29 Goligorsky MS, "Clinical assessment of endothelial dysfunction : combine and rule" 15 : 617-624, 2006

30 O’Riordan E, "Chronic NOS inhibition actuates endothelial–mesenchymal transformation" 292 : H285-H294, 2007

31 Tchkonia T, "Cellular senescence and the senescent secretory phenotype : therapeutic opportunities" 123 : 966-972, 2013

32 Melk A, "Cell senescence and its implications for Nephrology" 12 : 385-393, 2001

33 Pergola P, "Bardoxolone methyl and kidney function in CKD with type 2 diabetes" 365 : 327-336, 2011

34 De Zeeuw D, "BEACON Trial Investigators : Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease" 369 : 2492-2503, 2013